Bedside Biophysical-Semeiotic Diagnosis of Breast Cancer, since initial Stage.
Sergio Stagnaro, Biophysical Semeiotics Research Laboratory
6 December 2007
Sirs,
the authors write:"The typical clinical presentation of idiopathic granulomatous mastitis often mimics infection or malignancy". Unfortunately, it's clear that authors ignore Biophysical Semeiotics (1-5) (www.semeioticabiofisica.it). In addition, using breast cancer genetic risk assessment tools and going through the process of assessing breast cancer risk by this expensive way, can answer many women's questions about what puts them at relatively higher or lower risk. Certainly such as evaluation is to expensive for both NHS and single patient, and not applicable on women (and men!, of course) on very large scale.
In fact, based on 51 year-long clinical experience, for all women (and men!), an original clinical assessement may be desirable that in a easy and reliable manner allows to recognize the possible presence of maternally-inherited CAEMH-dependent, Oncological Terrain and oncological Real Risk, conditio sine qua non of cancer (1, 2), without following with genetic testing, but ascertaining especially breast cancer oncological INHERITED “real risk” in well-defined breast quadrant(s), characterized by newborn-pathological, type I, subtype a) i.e., oncological, Endoarteriolar Blocking Devices (1-5). In addition, testing for mutations of breast cancer susceptibility genes or for their diminished expression adds to our ability to assess breast cancer risk at an individual level. Really, we cannot localise in a (or more) mamma quadrant the possible breast cancer risk in BRCA 1 and BRCA 2, as well as a lot of other gene mutations-positive women (and men!). Biophysical Semeiotics (http://www.semeioticabiofisica.it, Breast Cancer in Practical Application; Oncological Terrain) allows doctor to recognize firstly oncological terrain in a quantitative way, and then, bu “not” in all cases, of course, breast cancer real risk: individuals with oncological terrain do not show generally real risk in all biological systems (3). Interestingly, the absence of both Oncological Terrain and breast oncological “Real Risk”, the later in a subject with Oncological Terrain, excludes beyond every doubt the possibility of occurrence of breast cancer (2, 3). As a consequence, we can perform nowadays an efficacious clinical, primary prevention of breast cancer (4), on very large scale, based on the Single Patient Based Medicine (5-10), as suggests also Planning for the EU public Health Portal at URL:
Finally, “real” sentinel limphonodes are trigger-points for autoimmune syndrome (3)
References
1) Stagnaro Sergio. There is another clinical, and overlooked tool, reliable in breast cancer prognosis evaluation , 2005. http://www.biomedcentral.com/1471-2407/5/70/comments#204473
2) Stagnaro Sergio, Stagnaro-Neri Marina. Introduzione alla Semeiotica Biofisica. Il Terreno oncologico. Travel Factory SRL., Roma, 2004.
3) Stagnaro-Neri M., Stagnaro S. Cancro della mammella: : prevenzione primaria e diagnosi precoce con la percussione ascoltata. Gazz. Med. It.; Arch. Sc. Med. 152, 447, 1993.
4) Stagnaro S. Lettera aperta al Ministro della Salute, Prof. G. Sirchia, sulla prevenzione primaria clinica del cancro mammario.
http://bmj.bmjjournals.com/cgi/eletters?lookup=by_date&days=1#72216 27 August 2004
5) Stagnaro S., Stagnaro-Neri M. Single Patient Based Medicine.La Medicina Basata sul Singolo Paziente: Nuove Indicazioni della Melatonina. Travel Factory SRL., Roma, 2005. http://www.travelfactory.it/semeiotica_biofisica.htm
6) Stagnaro S. Newborn-pathological Endoarteriolar Blocking Devices in Diabetic and Dislipidaemic Constitution and Diabetes Primary Prevention. The Lancet. March 06 2007. http://www.thelancet.com/journals/lancet/article/
PIIS0140673607603316/comments?totalcomments=1
7) Stagnaro Sergio. There is another clinical, and overlooked tool, reliable in breast cancer prognosis evaluation , 2005. http://www.biomedcentral.com/1471-2407/5/70/comments#204473
8) Stagnaro Sergio. "Genes, Oncological Terrain, and Breast Cancer" World Journal of Surgical Oncology., 2005, http://www.wjso.com/content/3/1/45/comments#205475
9) Stagnaro Sergio. Bed-Side Evaluating Breast Cancer Real Risk. World Journal of Surgical Oncology. 2005, 3:67 doi:10.1186/1477-7819-3-67. 2005
10) Stagnaro Sergio Mitochondrial Bed-Side Evaluation: a new Way in the War against Cancer (21 December 2005). Cancer Cell International http://www.cancerci.com/content/5/1/34/comments#218502
Bedside Biophysical-Semeiotic Diagnosis of Breast Cancer, since initial Stage.
6 December 2007
Sirs,
the authors write:"The typical clinical presentation of idiopathic granulomatous mastitis often mimics infection or malignancy". Unfortunately, it's clear that authors ignore Biophysical Semeiotics (1-5) (www.semeioticabiofisica.it). In addition, using breast cancer genetic risk assessment tools and going through the process of assessing breast cancer risk by this expensive way, can answer many women's questions about what puts them at relatively higher or lower risk. Certainly such as evaluation is to expensive for both NHS and single patient, and not applicable on women (and men!, of course) on very large scale.
In fact, based on 51 year-long clinical experience, for all women (and men!), an original clinical assessement may be desirable that in a easy and reliable manner allows to recognize the possible presence of maternally-inherited CAEMH-dependent, Oncological Terrain and oncological Real Risk, conditio sine qua non of cancer (1, 2), without following with genetic testing, but ascertaining especially breast cancer oncological INHERITED “real risk” in well-defined breast quadrant(s), characterized by newborn-pathological, type I, subtype a) i.e., oncological, Endoarteriolar Blocking Devices (1-5). In addition, testing for mutations of breast cancer susceptibility genes or for their diminished expression adds to our ability to assess breast cancer risk at an individual level. Really, we cannot localise in a (or more) mamma quadrant the possible breast cancer risk in BRCA 1 and BRCA 2, as well as a lot of other gene mutations-positive women (and men!). Biophysical Semeiotics (http://www.semeioticabiofisica.it, Breast Cancer in Practical Application; Oncological Terrain) allows doctor to recognize firstly oncological terrain in a quantitative way, and then, bu “not” in all cases, of course, breast cancer real risk: individuals with oncological terrain do not show generally real risk in all biological systems (3). Interestingly, the absence of both Oncological Terrain and breast oncological “Real Risk”, the later in a subject with Oncological Terrain, excludes beyond every doubt the possibility of occurrence of breast cancer (2, 3). As a consequence, we can perform nowadays an efficacious clinical, primary prevention of breast cancer (4), on very large scale, based on the Single Patient Based Medicine (5-10), as suggests also Planning for the EU public Health Portal at URL:
http://www.google.it/search?q=cache:U5A-DtWmRDsJ:europa.eu.int/comm/health/ph_information/documents/ev_20030710_co01_en.pdf+single+patient+based+medicine+and+stagnaro&hl=it&ie=UTF-8 Pg 36.
Finally, “real” sentinel limphonodes are trigger-points for autoimmune syndrome (3)
References
1) Stagnaro Sergio. There is another clinical, and overlooked tool, reliable in breast cancer prognosis evaluation , 2005. http://www.biomedcentral.com/1471-2407/5/70/comments#204473
2) Stagnaro Sergio, Stagnaro-Neri Marina. Introduzione alla Semeiotica Biofisica. Il Terreno oncologico. Travel Factory SRL., Roma, 2004.
http://www.travelfactory.it/semeiotica_biofisica.htm
3) Stagnaro-Neri M., Stagnaro S. Cancro della mammella: : prevenzione primaria e diagnosi precoce con la percussione ascoltata. Gazz. Med. It.; Arch. Sc. Med. 152, 447, 1993.
4) Stagnaro S. Lettera aperta al Ministro della Salute, Prof. G. Sirchia, sulla prevenzione primaria clinica del cancro mammario.
http://www.katamed.it/Notizia.asp?id=8094&lingua=IT&idcat=999;
http://xoomer.virgilio.it/piazzetta/professione/professione.htm
http://www.ilpungolo.com/site/leggi.asp?NWS=2390&IDS=10.
http://bmj.bmjjournals.com/cgi/eletters?lookup=by_date&days=1#72216 27 August 2004
5) Stagnaro S., Stagnaro-Neri M. Single Patient Based Medicine.La Medicina Basata sul Singolo Paziente: Nuove Indicazioni della Melatonina. Travel Factory SRL., Roma, 2005. http://www.travelfactory.it/semeiotica_biofisica.htm
6) Stagnaro S. Newborn-pathological Endoarteriolar Blocking Devices in Diabetic and Dislipidaemic Constitution and Diabetes Primary Prevention. The Lancet. March 06 2007. http://www.thelancet.com/journals/lancet/article/
PIIS0140673607603316/comments?totalcomments=1
7) Stagnaro Sergio. There is another clinical, and overlooked tool, reliable in breast cancer prognosis evaluation , 2005. http://www.biomedcentral.com/1471-2407/5/70/comments#204473
8) Stagnaro Sergio. "Genes, Oncological Terrain, and Breast Cancer" World Journal of Surgical Oncology., 2005, http://www.wjso.com/content/3/1/45/comments#205475
9) Stagnaro Sergio. Bed-Side Evaluating Breast Cancer Real Risk. World Journal of Surgical Oncology. 2005, 3:67 doi:10.1186/1477-7819-3-67. 2005
10) Stagnaro Sergio Mitochondrial Bed-Side Evaluation: a new Way in the War against Cancer (21 December 2005). Cancer Cell International http://www.cancerci.com/content/5/1/34/comments#218502
Competing interests
None declared